EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Aseptic meningitis induced by monoclonal antibodies used in cancer treatment: a systematic review

Nasibeh Ghalandari, Sara Ataei, Fahime Nasr Esfahani, Shahaboddin Emami

Research in Pharmaceutical Sciences · 2026-05 · 21 (3) · 262-277

DOI: 10.4103/rps.rps_236_24 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Research in Pharmaceutical Sciences, online erschienen am 10.05.2026. Verfasst von Nasibeh Ghalandari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Research Center, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, I.…. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose: Monoclonal antibodies (MAbs) have revolutionized cancer treatment but are associated with a spectrum of adverse events, including neurological complications. Understanding the mechanism and management of complications is crucial for optimizing patient care. The present systematic review aimed to identify case reports of MAbs used for cancer treatment that resulted in aseptic meningitis (AM). Methods: Databases including Google Scholar, PubMed, and Scopus were searched for studies published until March 2024 (updated in May 2025). The Joanna Briggs Institute (JBI) critical appraisal checklist was used to assess the quality of case report studies, and the methodological quality of the included studies was considered acceptable. Findings/Results: In total, 32 articles were analyzed in the present systematic review. Cetuximab had the highest reported incidence of AM, while rituximab, daratumumab, and apolizumab had the lowest prevalence. The quality of the studies was also acceptable. Conclusion and implications: AM appears to occur more frequently with monoclonal antibodies than with conventional drug structures. Prompt recognition of the underlying mechanisms can help physicians manage these complications more effectively.

Schlagwörter

Stichwörter der Autor:innen

Aseptic meningitisCancer immunotherapyDrug-induced adverse effectMonoclonal antibodiesReview.

Autor:innen und Institutionen

  • Pharmaceutical Sciences Research Center, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, I.R. Iran.
  • Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, I.R. Iran.
  • 13Aban Pharmacotherapy Clinic, Tehran University of Medical Sciences (TUMS), Tehran, I.R. Iran.

Zitieren

APA

Ghalandari, N., Ataei, S., Esfahani, F. N., & Emami, S. (2026). Aseptic meningitis induced by monoclonal antibodies used in cancer treatment: a systematic review. Research in Pharmaceutical Sciences, 21(3), 262-277. https://doi.org/10.4103/rps.rps_236_24

Vancouver

Ghalandari N, Ataei S, Esfahani FN, Emami S. Aseptic meningitis induced by monoclonal antibodies used in cancer treatment: a systematic review. Research in Pharmaceutical Sciences. 2026;21(3):262-277. doi:10.4103/rps.rps_236_24

BibTeX
@article{Ghalandari2026,
  author = {Ghalandari, Nasibeh and Ataei, Sara and Esfahani, Fahime Nasr and Emami, Shahaboddin},
  title = {Aseptic meningitis induced by monoclonal antibodies used in cancer treatment: a systematic review},
  journal = {Research in Pharmaceutical Sciences},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {262--277},
  doi = {10.4103/rps.rps_236_24}
}
Kostenlos starten →